Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.202200688NEW FUCOSYLTRANSFERASE FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES
DK 16.02.2024
Int.Class C12N 15/70
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
70Vectors or expression systems specially adapted for E. coli
Appl.No PA 2022 00688 Applicant DSM IP Assets B.V. Inventor Manos PAPADAKIS
The present invention relates to the production of fucosylated Human Milk Oligosaccharides (HMOs), and in particular to the production of complex fucosylated HMOs with five or more monosaccharide units such as LNFP-II, LNFP-III and LNDFH-I from precursor oligosaccharides and the genetic engineering of suitable cells for use in said production, as well as to methods for producing said fucosylated HMOs.
2.202201203NEW FUCOSYLTRANSFERASES FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES
DK 16.02.2024
Int.Class C12N 1/21
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
21modified by introduction of foreign genetic material
Appl.No PA 2022 01203 Applicant DSM IP Assets B.V. Inventor Manos Papadakis
The present invention relates to the production of fucosylated Human Milk Oligosaccharides (HMOs), and in particular to the production of complex fucosylated HMOs with five or more monosaccharide units, such as LNFP-V and LNDFH-II, from precursor oligosaccharides and the genetic engineering cells and α-1,3(4)-fucosyltransferases suitable for use in said production of suitable for use in said production, as well as to methods for producing said fucosylated HMOs.
3.20240052002TOMATO-DERIVED SIJUL GENE REGULATING PHLOEM DEVELOPMENT AND USE THEREOF
US 15.02.2024
Int.Class C07K 14/415
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
415from plants
Appl.No 18365274 Applicant POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION Inventor Ho Young NAM

The present invention relates to a composition for enhancing the sink strength of a sink tissue of a plant. The composition can increase the number of phloem cells and phloem transport velocity by suppressing the expression of an SlJUL protein or a gene encoding the SlJUL protein. Therefore, the present invention can be usefully used to increase the productivity and yield of agricultural crops.

4.20240052296METHOD FOR PRODUCING COLANIC ACID USING RECOMBINANT ESCHERICHIA COLI
US 15.02.2024
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No 17819767 Applicant Korea University Research and Business Foundation Inventor Kyoung Heon KIM

The present invention relates to an optimum method for mass-producing colanic acid by changes in the genetic factors of the strain and the environmental factors of the strain culture. The biological production amount of colanic acid can be significantly increased using the recombinant strain and culture conditions of the present invention.

5.20240052328COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING LOW-DENSITY LIPOPROTEIN THROUGH TARGETED GENE REPRESSION
US 15.02.2024
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No 18479758 Applicant Tune Therapeutics, Inc. Inventor Jennifer KWON

Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems for the transcriptional repression of genes to promote a cellular phenotype that leads to reduction of low-density lipoprotein (LDL). In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof that regulate LDL. In some embodiments, the systems are multiplexed systems that bind to or target a target site in at least two genes or regulatory elements thereof. Also provided herein are methods and uses related to the provided epigenetic-modifying DNA targeting systems in connection with treatments for cardiovascular disease and familial hypercholesterolemia.

6.20240052346METHODS FOR PRODUCING EXTRACELLULAR VESICLES ENRICHED IN ANTI-INFLAMMATORY MICRORNAS
US 15.02.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No 18259603 Applicant Cellular Biopharma(Shanghai) Ltd. Inventor Ping LI

Provided are methods of producing exosomes by culturing isolated stem cells with an effective amount of at least one immunoregulatory factor. The thus-produced exosomes are enriched in anti-inflammatory miRNAs and/or miRNAs that inhibits the a epithelial-mesenchymal transition.

7.20240052000MUTATED HOST CELLS WITH REDUCED CELL MOTILITY ON
US 15.02.2024
Int.Class C07K 14/32
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195from bacteria
32from Bacillus (G)
Appl.No 18257840 Applicant Novozymes A/S Inventor Thomas Krogh Kallehauge

The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.

8.WO/2024/032012PHENYLALANINE AMMONIA LYASE MUTANT AND USE THEREOF
WO 15.02.2024
Int.Class C12N 9/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
88Lyases (4.)
Appl.No PCT/CN2023/087182 Applicant BIOCREATECH (SHENZHEN) BIOTECHNOLOGY CO., LTD Inventor CHAI, Chengcheng
Provided are a phenylalanine ammonia lyase mutant, an encoding gene thereof, a genetically engineered microorganism, and a method for preparing the phenylalanine ammonia lyase mutant. Also provided is use of the phenylalanine ammonia lyase mutant in catalyzing the degradation of L-phenylalanine and preparing an oral medicament for treating phenylketonuria.
9.WO/2024/031187A POLYNUCLEOTIDE-MODIFYING ENZYME COMPRISING A PEPTIDIC RECOGNITION SEQUENCE
WO 15.02.2024
Int.Class C12N 9/22
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
16acting on ester bonds (3.1)
22Ribonucleases
Appl.No PCT/CA2023/051060 Applicant JENTHERA THERAPEUTICS INC. Inventor ROCHE, Philip
There is provided a polynucleotide-modifying enzyme with a functional nuclease domain and a display domain. The functional nuclease domain comprises a nuclease catalytic pocket. The display domain comprises a peptidic recognition sequence of from 3 to 20 amino acids in length, in a loop, an alpha helix or an extension off the end of the alpha helix that is positioned on an external surface of the polynucleotide-modifying enzyme. The peptidic recognition sequence recognizes a target cell receptor of a target cell to allow cell internalization of the polynucleotide- modifying enzyme in said target cell.
10.WO/2024/033467ALLELE SPECIFIC SIRNA THERAPY FOR DYNAMIN 2-RELATED DISEASES
WO 15.02.2024
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2023/072157 Applicant INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Inventor BITOUN, Marc
The present invention relates to the treatment of myopathy. The inventors report the identification of effective AS-siRNA against the two nucleotide versions of the two non- pathogenic DNM2 SNPs which may be used to silence any mutation carried by the same mRNA. In addition, the first AS-siRNAs targeting a DNM2 mutation associated with severe neonatal phenotype, i.e. the p.S619L mutation, have been developed and in a second time, they developed other AS-siRNA targeting the mutation p.S619L and the mutation p.R465W. They also report the functional benefits of this new set of siRNAs on several defects identified in patient-derived cell lines. The development of these new AS-siRNA, in addition to the previous ones against the p.R465W mutation, provides a panoply of allele-specific molecules able to target the large majority of AD-CNM patients. Interestingly, siRNAs against the DNM2 SNPs represent versatile molecules with larger potential applications to silence DNM2 mutations in CMT and HSP and to reduce DNM2 expression in a controlled manner in diseases associated with deleterious overexpression. Thus, the present invention relates to an allele specific siRNA (AS-siRNA) able to silence the expression of only one allele of a heterozygous DNM2 gene wherein the targeted allele comprises a non-pathological polymorphism selected from the group consisting of rs2229920 (C or T) or rs12461992 (A or T) and/or a disease-causing mutation selected from the group consisting of c.1393C>T or c.1856C>T.